The publication of this infographic was funded by AstraZeneca , and is intended for US Healthcare Professionals.
Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling.
Please see full Prescribing Information , including Patient Information when making treatment decisions.
In a recent US real-world observational study in patients with metastatic breast cancer, both the occurrence of hyperglycemia and the requirement for antihyperglycemic medications were lower with capivasertib than with other PI3K/AKT pathway inhibitors.
The infographic also sets out practical steps to prevent, monitor, and treat hyperglycemia during capivasertib therapy: preparing proactively before Day 1, monitoring FG and counseling patients, starting or increasing metformin, withholding capivasertib until FG ≤160 mg/dL, following resume rules, and keeping patients on treatment.
The publication of this infographic was funded by AstraZeneca , and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information , including Patient Information when making treatment decisions.
Glucose elevations with capivasertib were manageable in the CAPItello-291 trial: approximately 37% of patients had an any-grade increase in fasting glucose (FG) from baseline, with a median time to first occurrence of 15 days, and 0.6% of patients each had dose reductions and permanent discontinuations due to hyperglycemia. In a recent US real-world observational study in patients with metastatic breast cancer, both the occurrence of hyperglycemia and the requirement for antihyperglycemic medications were lower with capivasertib than with other PI3K/AKT pathway inhibitors.
The infographic also sets out practical steps to prevent, monitor, and treat hyperglycemia during capivasertib therapy: preparing proactively before Day 1, monitoring FG and counseling patients, starting or increasing metformin, withholding capivasertib until FG ≤160 mg/dL, following resume rules, and keeping patients on treatment. An illustrative example shows the recommended action at each FG level. Some key recommendations are based on expert panel consensus.
